ライフサイエンスコーパス: cystectomy

1 elvic lymphadenectomy at the time of radical cystectomy.

2 ence of chronic kidney damage after subtotal cystectomy.

3 orting the use of minimally invasive radical cystectomy.

4 curative therapeutic alternatives to radical cystectomy.

5 evaluated from 1 to 26 weeks after subtotal cystectomy.

6 e timing of intravesical therapy and radical cystectomy.

7 in young animals at 26 weeks after subtotal cystectomy.

8 ain a complication within 90 days of radical cystectomy.

9 mbers of patients who are not candidates for cystectomy.

10 is an acceptable alternative to open radical cystectomy.

11 ng other patients toxic effects and delay to cystectomy.

12 rging minimally invasive approach to radical cystectomy.

13 abstracts related to robot-assisted radical cystectomy.

14 he scientific practice of LND during radical cystectomy.

15 ved convalescence compared with open-radical cystectomy.

16 ve complications with robot-assisted radical cystectomy.

17 logic outcomes as compared with open radical cystectomy.

18 d a retrospective comparison to open radical cystectomy.

19 ible, minimally invasive approach to radical cystectomy.

20 d outcomes related to robot-assisted radical cystectomy.

21 patients underwent FDG-PET/CT before planned cystectomy.

22 spared the unnecessary morbidity of radical cystectomy.

23 ite recurrence, and overtreatment with early cystectomy.

24 in making treatment decisions before radical cystectomy.

25 an achieve survival rates similar to radical cystectomy.

26 tine, doxorubicin, and cisplatin followed by cystectomy.

27 solidation CRT to 64 Gy and others underwent cystectomy.

28 egies particularly as they relate to radical cystectomy.

29 gement of muscle invasive disease is radical cystectomy.

30 ogic outcomes compare well with open radical cystectomy.

31 e disease continues to be managed by radical cystectomy.

32 nitial experiences with laparoscopic radical cystectomy.

33 were unable or unwilling to undergo radical cystectomy.

34 5-year disease recurrence risk after radical cystectomy.

35 a viable option for some patients who refuse cystectomy.

36 s are markers of improved outcome of radical cystectomy.

37 determined before, during, and after radical cystectomy.

38 al recurrence (LR) in all patients receiving cystectomy.

39 bladder cancer who were treated with radical cystectomy.

40 own to correlate with survival after radical cystectomy.

41 invasive bladder cancer who received radical cystectomy.

42 bladder cancer who were treated with radical cystectomy.

43 xorubicin, and cisplatin followed by radical cystectomy.

44 to T4a) and were to be treated with radical cystectomy.

45 on bladder tumor, most still require radical cystectomy.

46 s in the bladder, and survival after salvage cystectomy.

47 Those with less than a CR underwent cystectomy.

48 bladder from patients that underwent radical cystectomy.

49 carcinoma of the urinary bladder is radical cystectomy.

50 with neoadjuvant chemotherapy and (radical) cystectomy.

51 combination chemotherapy followed by radical cystectomy.

52 (2003-2012) treated with chemotherapy and/or cystectomy.

53 mine the stage of the disease before radical cystectomy.

54 Of these 2 patients, one required radical cystectomy.

55 considerable debate about the role of early cystectomy.

56 noma of the bladder have poor survival after cystectomy.

57 patients are unwilling or unable to undergo cystectomy.

58 ients who underwent NAC, followed by radical cystectomy.

59 of concerns regarding toxicity and delay to cystectomy.

60 dMVAC were administered, followed by radical cystectomy.

61 nd counseling of patients undergoing radical cystectomy.

62 utilized to measure HRQOL following radical cystectomy.

63 agectomy, pancreatectomy, lung resection, or cystectomy.

64 important outcome measure following radical cystectomy.

65 rizable urinary reservoirs following radical cystectomy.

66 ctures per 100 person-years in those without cystectomy.

67 analysis included 31,191 colectomies, 2,670 cystectomies, 1,514 pancreatectomies, 2,607 proctectomie

68 Four thousand nine hundred forty cystectomies, 1,573 esophagectomies, 20,362 lung resecti

69 ity for pancreatectomy (67% of the decline), cystectomy (37%), and esophagectomy (32%), but not for t

70 our understanding of HRQOL following radical cystectomy, a lack of prospective studies limits conclus

71 with no residual muscle-invasive disease at cystectomy after neoadjuvant chemotherapy were likely to

72 tors influence bladder cancer outcomes after cystectomy, after adjustment for pathologic factors and

73 eveloped metastases and thus did not undergo cystectomy; all others (n = 43) proceeded to cystectomy

74 d benefits of radical cystectomy over simple cystectomy alone are accepted, an optimal template for p

75 enefit of adjuvant chemotherapy over radical cystectomy alone for muscle-invasive bladder cancer.

76 In cisplatin-ineligible patients, radical cystectomy alone is recommended.

77 sease) and were randomly assigned to radical cystectomy alone or three cycles of methotrexate, vinbla

78 The crude 5-year OS for chemotherapy alone, cystectomy alone, preoperative chemotherapy followed by

79 Compared with cystectomy alone, preoperative chemotherapy was associat

80 As compared with radical cystectomy alone, the use of neoadjuvant methotrexate, v

81 orable clinical outcomes relative to radical cystectomy alone.

82 ficant improvement in survival compared with cystectomy alone.

83 rapy alone was worse than those treated with cystectomy alone.

84 rowth and experience in laparoscopic radical cystectomy, along with continuing refinements in techniq

85 neoadjuvant chemotherapy followed by radical cystectomy, an approach that could result in significant

86 N1, 48%; cN2, 45%; cN3, 7%), 1,104 underwent cystectomy and 635 were treated with chemotherapy alone.

87 T1 or worse, we recommended patients undergo cystectomy and adjuvant chemotherapy.

88 o evidence of an interaction between radical cystectomy and age, sex, comorbidity score, or cancer st

89 e versus deferred chemotherapy after radical cystectomy and bilateral lymphadenectomy for patients wi

90 ical outcomes of patients treated by radical cystectomy and bilateral lymphadenectomy for urothelial-

91 de positive (pN1-3) M0 disease after radical cystectomy and bilateral lymphadenectomy, with no eviden

92 Neoadjuvant therapy before cystectomy and consolidation therapy with biological age

93 f cell-free DNA in patients before and after cystectomy and during chemotherapy.

94 ues has prompted interest in robotic radical cystectomy and extended PLND, and recent reports have de

95 ive morbidity following contemporary radical cystectomy and identify preoperative, intraoperative, an

96 We assessed whether radical cystectomy and intestinal urinary diversion are associat

97 omparison between minimally invasive radical cystectomy and open radical cystectomy is needed to defi

98 on to technique, especially in nerve-sparing cystectomy and orthotopic cystoplasty may reduce the rat

99 ne, doxorubicin, and cisplatin) plus radical cystectomy and pelvic lymph node dissection.

100 Radical cystectomy and pelvic lymphadenectomy (PLND) remains the

101 hat may benefit from integrated therapy with cystectomy and perioperative systemic chemotherapy.

102 mally invasive techniques to perform radical cystectomy and PLND have been adopted.

103 consisting of patients treated with radical cystectomy and PLND.

104 We evaluated the association between radical cystectomy and risk of fracture at any site, controlling

105 inent diversion can decrease the interval to cystectomy and therefore may impact positively on surviv

106 outcomes between patients undergoing radical cystectomy and TMT.

107 ry protocols for patients undergoing radical cystectomy and urinary diversion and describe our unique

108 atients with bladder cancer who have radical cystectomy and urinary diversion are at increased risk o

109 ical prostatectomy), bladder cancer (radical cystectomy and urinary diversion for muscle invasive bla

110 Radical cystectomy and urinary diversion may cause chronic metab

111 isease, more aggressive therapy with radical cystectomy and urinary diversion or trimodal therapy wit

112 tolerated and effective alternative to open cystectomy and urinary diversion.

113 included 50,520 patients, of whom 4,878 had cystectomy and urinary diversion.

114 urothelial cancer of the bladder treated by cystectomy and/or radiotherapy.

115 uccessfully treated with salvage therapy via cystectomy, and 16 patients (16%) died of disease.

116 46 percent for esophagectomy, 39 percent for cystectomy, and 24 percent for lung resection.

117 alone, preoperative chemotherapy followed by cystectomy, and cystectomy followed by adjuvant chemothe

118 ed at diagnosis, during chemotherapy, before cystectomy, and during surveillance.

119 oung) and 12 months (old) underwent subtotal cystectomy, and then were evaluated from 1 to 26 weeks a

120 tomy are lacking, minimally invasive radical cystectomy appears to have superior perioperative outcom

121 ostatectomy and reconstruction after radical cystectomy are discussed.

122 Although rigorous comparisons with open cystectomy are lacking, minimally invasive radical cyste

123 rm outcomes after minimally invasive radical cystectomy are limited, intermediate term oncologic outc

124 ve, randomized comparisons with open radical cystectomy are needed as this technique continues to be

125 ized prospective comparisons to open radical cystectomy are needed to further validate this procedure

126 management of the urethra before and during cystectomy as well as afterwards.

127 iveness and harms of both minimally invasive cystectomy as well as the optimal extent of pelvic lymph

128 extirpative portion of laparoscopic radical cystectomy at multiple institutions.

129 onary resection, hepatectomy, colectomy, and cystectomy) between 2010 and 2012 were identified from t

130 At 26 weeks after subtotal cystectomy, bladder capacity in young animals was indist

131 edures (pancreatic resection, esophagectomy, cystectomy), but longer for other procedures (aortic and

132 Morbidity is common following radical cystectomy, but careful attention to preoperative, intra

133 ion in those undergoing laparoscopic radical cystectomy, but these observations have not been corrobo

134 e last year, numerous robot-assisted radical cystectomy case series with larger cohorts have been pub

135 approach the yield seen at high-volume open cystectomy centers, but a larger proportion of robotic l

136 c survival compared with the high-expression cystectomy cohort (69.9% versus 53.8% 3-year CSS, P = 0.

137 However, in the cystectomy cohort (n = 88), MRE11 expression was not ass

138 Neoadjuvant chemotherapy before cystectomy confers a survival benefit in bladder cancer,

139 1.21; 95% CI, 1.10 to 1.32) compared with no cystectomy, controlling for patient and disease characte

140 After cystectomy, ctDNA analysis correctly identified all pati

141 While radical cystectomy cures many patients with this tumor, almost 5

142 Institutional radical cystectomy databases containing detailed information on

143 zed trial comparing open and robotic radical cystectomy demonstrated equivalent lymph node yields.

144 affect treatment as feasibility for radical cystectomy depends on staging by a combination of clinic

145 Patients undergoing colectomy, cystectomy, esophagectomy, gastrectomy, hysterectomy, lu

146 ) after six cancer surgeries (prostatectomy, cystectomy, esophagectomy, pancreatectomy, pneumonectomy

147 nd variant histology should be offered early cystectomy, especially if harboring pure squamous, adeno

148 n be considered as an alternative to radical cystectomy, especially in elderly patients not well suit

149 th lymph node-positive disease after radical cystectomy, even in the context of adjuvant chemotherapy

150 In patients undergoing cystectomy, evidence supports the need for an adequate l

151 ive chemotherapy followed by cystectomy, and cystectomy followed by adjuvant chemotherapy was 14% (95

152 otherapy, or, alternatively, to have initial cystectomy followed by five cycles of adjuvant chemother

153 bilateral pelvic lymphadenectomy and radical cystectomy for bladder cancer (median follow-up, 101 mon

154 spective study of 958 patients who underwent cystectomy for bladder cancer between 1984 and 2003.

155 ed quality of life (HRQOL) following radical cystectomy for bladder cancer is an important outcome me

156 Minimally invasive radical cystectomy for bladder cancer is performed laparoscopica

157 uggests that all patients undergoing radical cystectomy for bladder cancer should undergo concomitant

158 ram predicting recurrence risk after radical cystectomy for bladder cancer.

159 gastrectomy, colectomy, lung resection, and cystectomy for cancer from 2003 through 2007 were studie

160 glucose (FDG) in patients undergoing radical cystectomy for cT2-3N0M0 urothelial carcinoma of the bla

161 c splenic procedures were performed: splenic cystectomy for epithelial (4) or traumatic (2) cyst, and

162 and overall survival in patients who undergo cystectomy for invasive bladder cancer and are node-nega

163 xpression and overall survival after radical cystectomy for invasive bladder cancer.

164 l and quality of life of patients undergoing cystectomy for invasive bladder cancer.

165 le-invasive bladder cancer (MIBC), reserving cystectomy for salvage treatment.

166 nimally invasive alternative to open radical cystectomy for the treatment of bladder cancer.

167 had no residual disease than patients in the cystectomy group (38 percent vs. 15 percent, P<0.001).

168 The incidence of fracture in the cystectomy group was 6.55 fractures per 100 person-years

169 A significant regionalization of cystectomy has already been established.

170 dissection performed at the time of radical cystectomy has an ability to improve locoregional diseas

171 eutic role of lymphadenectomy during radical cystectomy has become apparent and recent work has attem

172 However, the risk of fractures after radical cystectomy has not been defined.

173 ent of the urethra before, during, and after cystectomy, however, is still not standardized.

174 erative outcomes are as good as open radical cystectomy if not better.

175 adiation therapy, chemotherapy) with salvage cystectomy, if necessary, can achieve survival rates sim

176 sacrectomy in 170 patients (32%), and total cystectomy in 105 patients (20%).

177 tein expression to predict outcome following cystectomy in 257 patients enrolled in two independent c

178 otherapy may be offered as an alternative to cystectomy in appropriately selected patients with MIBC

179 .60-0.75) for prediction of nodal disease at cystectomy in AUO-AB-05/95.

180 an achieve similar lymph node counts as open cystectomy in experienced hands and with careful patient

181 lso help define selection criteria for early cystectomy in HGT1 bladder cancer, particularly for pati

182 o emerge and appears similar to open-radical cystectomy in nonrandomized comparisons.

183 Radiotherapy is an alternative to cystectomy in patients with muscle-invasive bladder canc

184 based combination chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial

185 Ten-year survival can still be achieved with cystectomy in the face of grossly positive lymph nodes i

186 f approximately 70% of the bladder (subtotal cystectomy) in 12-week-old female rats induced complete

187 the RC arm, 20 (80.0%) participants received cystectomy, including five (25.0%) with no tumor, 13 (65

188 xorubicin, and cisplatin followed by radical cystectomy increases the likelihood of eliminating resid

189 are limited data on robotic assisted radical cystectomy, initial reports suggest that an appropriate

190 lymph node dissection at the time of radical cystectomy is a crucial component of the surgical manage

191 Radical cystectomy is a morbid procedure with rather long hospit

192 Robot-assisted radical cystectomy is a reproducible, minimally invasive approac

193 espond to intravesical agents, in whom early cystectomy is advocated.

194 Robot-assisted radical cystectomy is an emerging minimally invasive approach to

195 ls in >50% of cases, and second-line radical cystectomy is associated with overtreatment and drastic

196 Laparoscopic radical cystectomy is being increasingly performed at several ce

197 Robot-assisted radical cystectomy is being more widely studied as a potential a

198 invasive radical cystectomy and open radical cystectomy is needed to define the role of these modalit

199 ents with MIBC and in some patients for whom cystectomy is not an option.

200 finements in technique, laparoscopic radical cystectomy is now being performed at many centers worldw

201 most important predictor of recurrence after cystectomy is pathologically positive nodes, our aim was

202 Robot-assisted radical cystectomy is steadily growing with a feasible learning

203 The prevalence of robot-assisted radical cystectomy is steadily increasing.

204 sus adjuvant chemotherapy around the time of cystectomy is still debated, though the best level-one e

205 sus adjuvant chemotherapy around the time of cystectomy is still debated.

206 Minimally invasive radical cystectomy is technically feasible.

207 Early cystectomy is the standard of care for BCG failure; howe

208 Radical cystectomy is the standard of care for patients who fail

209 ined-modality therapy, with chemotherapy and cystectomy, is associated with the best outcomes.

210 it is superseding pure laparoscopic radical cystectomy (LRC) at centers, where robot is available an

211 as unrelated to mortality for esophagectomy, cystectomy, lung resection, aortic valve replacement, or

212 Radical cystectomy may include resection of adjacent organs and

213 15 (38%; 95% CI, 23% to 53%) showing pT0 at cystectomy, meeting the primary end point of the study.

214 gical efficacy of minimally invasive radical cystectomy (MIRC) and PLND.

215 For patients unwilling or unable to undergo cystectomy, numerous local therapies exist, although few

216 Thirteen patients required a salvage cystectomy, of whom 6 died, which includes 4 (9%) from a

217 or burden, defined as the receipt of radical cystectomy or >/= 50 Gy of radiation therapy delivered t

218 tools developed to help stratify patients to cystectomy or bladder-sparing regimens.

219 cancer, 151 were treated by standard radical cystectomy or by definitive TUR, if restaging TUR of the

220 py of his primary bladder tumor with radical cystectomy or radiation.

221 viewed as state of the art, as compared with cystectomy or radiotherapy alone, for deeply invasive bl

222 ypass, lung resection, pancreatic resection, cystectomy, or esophagectomy.

223 Open radical cystectomy (ORC) and pelvic lymph node dissection (PLND)

224 Although the added benefits of radical cystectomy over simple cystectomy alone are accepted, an

225 ed with 71% of 52 patients who had immediate cystectomy (P: = .3).

226 ancer outcome in patients undergoing radical cystectomy, p53 is the strongest predictor, followed by

227 rysm repair, carotid endarterectomy, radical cystectomy, pancreatic resection, and esophagectomy.

228 Of the cystectomy patients, 363 received preoperative and 328 r

229 with radical radiotherapy and one cohort of cystectomy patients.

230 ications for improving perioperative care of cystectomy patients.

231 Within 90 days of cystectomy, patients were centrally randomly assigned (1

232 ence suggests that outcome is improved after cystectomy performed at high-volume centers and by high-

233 mpare the effectiveness of cystectomy versus cystectomy plus adjuvant chemotherapy in real-world pati

234 ladder neck contracture postprostatectomy or cystectomy presents a reconstructive challenge combined

235 abdominal aortic aneurysm repair, colectomy, cystectomy, prostatectomy, lung resection, total knee ar

236 tered markers in patients treated by radical cystectomy provides prognostic information that could he

237 ples for technique of robot-assisted radical cystectomy (RARC) based on current peer reviewed literat

238 Robot-assisted radical cystectomy (RARC) continues to provide a minimally invas

239 and current status of robot-assisted radical cystectomy (RARC) with pelvic lymphadenectomy (PLND) and

240 Although radical cystectomy (RC) currently is viewed as the standard of c

241 Bacillus Calmette-Guerin (mBCG) and radical cystectomy (RC).

242 neoadjuvant chemotherapy followed by radical cystectomy (RC).

243 cancer-related surgical procedures (radical cystectomy [RC], radical nephrectomy [RN], and radical p

244 might have implications in terms of radical cystectomy recommendation in MPBC patients.

245 oncologic outcomes with laparoscopic radical cystectomy remain undefined, and appropriate lymph node

246 Radical cystectomy remains the gold-standard therapy for invasiv

247 gement guidelines are less clear and radical cystectomy remains the mainstay of treatment at this tim

248 While radical cystectomy remains the mainstay of treatment for muscle-

249 ion of high-risk superficial bladder cancer, cystectomy remains the standard of care for the patient

250 sus adjuvant chemotherapy around the time of cystectomy remains to be resolved.

251 eumonectomy, 2 to 5 percent for gastrectomy, cystectomy, repair of a nonruptured abdominal aneurysm,

252 In patients undergoing cystectomy, reports using more standardized measures of

253 Optimal outcomes following radical cystectomy require an extended lymph node dissection, ne

254 ed immunohistochemically on archival radical cystectomy samples from 164 patients with invasive or hi

255 rates of overall survival similar to radical cystectomy series.

256 o be equivalent to contemporary open radical cystectomy series.

257 oncologic outcome data, laparoscopic radical cystectomy should be considered an investigative techniq

258 lihood of eliminating residual cancer in the cystectomy specimen and is associated with improved surv

259 d with the absence of residual cancer in the cystectomy specimen.

260 perimposed histologic and genetic mapping in cystectomy specimens and was verified in urinary bladder

261 16 were performed on 234 DNA samples of five cystectomy specimens from patients with invasive bladder

262 Cystectomy specimens obtained after radical surgery were

263 and 5 muscle controls) from 26 fresh-frozen cystectomy specimens.

264 long-term DSS comparable to modern immediate cystectomy studies, for patients with similarly staged M

265 Eleven patients (37%) underwent a cystectomy subsequent to gemcitabine therapy.

266 For esophagectomy, lung resection, and cystectomy, the adjusted odds of individual mortality in

267 c outcomes appear comparable to open radical cystectomy, the reference standard.

268 early aggressive intervention (i.e., radical cystectomy), then treatment recommendations should refle

269 allow patient selection for radiotherapy or cystectomy, thus improving overall cure rates.

270 s ratio (OR) of 1.3 (95% CI, 0.8 to 2.3) for cystectomy to 4.9 (95% CI, 2.4 to 10.1) for pancreatecto

271 d third terciles of cost varied from 27% for cystectomy to 40% for colectomy.

272 current experience with laparoscopic radical cystectomy to identify its role in oncological bladder s

273 lymph node dissection at the time of radical cystectomy to optimize oncologic outcomes.

274 p, we sought to compare the effectiveness of cystectomy versus cystectomy plus adjuvant chemotherapy

275 or standard urothelial cell carcinoma (early cystectomy vs. intravesical therapy).

276 patients who did not have a progression or a cystectomy was 19 months (range, 2 to 35 months).

277 Median time from start of chemotherapy to cystectomy was 9.7 weeks.

278 Cystectomy was associated with a 21% greater risk of fra

279 Transplant nephrectomy with cystectomy was performed as a secondary treatment in one

280 Salvage cystectomy was performed in 6 (10.7%) of 56 patients who

281 Cystectomies were performed by 106 surgeons in 109 insti

282 t to intravesical BCG therapy and refusing a cystectomy were considered eligible for the trial.

283 Calmette-Guerin (BCG) therapy and refusing a cystectomy were considered eligible for the trial.

284 a of the bladder who were not candidates for cystectomy were eligible.

285 Radical cystectomy with an appropriate lymph node dissection and

286 All patients undergoing radical cystectomy with bilateral pelvic iliac lymphadenectomy,

287 Radical cystectomy with bilateral pelvic lymph node dissection r

288 ease in the United States centers on radical cystectomy with bilateral pelvic lymphadenectomy.

289 Laparoscopic radical cystectomy with extended lymphadenectomy provides short-

290 s regarding the clinical benefits of radical cystectomy with extended lymphadenectomy, and will also

291 urvival rates in patients undergoing radical cystectomy with extended PLND, even in cases of patholog

292 AMVAC with pegfilgrastim followed by radical cystectomy with lymph node dissection.

293 ncer, multimodal treatment involving radical cystectomy with neoadjuvant chemotherapy offers the best

294 Radical cystectomy with pelvic lymph node dissection (PLND) is t

295 neoadjuvant chemotherapy followed by radical cystectomy with pelvic lymph node dissection, which disc

296 the current status of robot-assisted radical cystectomy with pelvic lymphadenectomy and urinary diver

297 Radical cystectomy with thorough pelvic lymphadenectomy remains

298 Robot-assisted radical cystectomy with urinary diversion appears to be growing

299 tandard of care in these patients is radical cystectomy with urinary diversion, but this approach is

300 cystectomy; all others (n = 43) proceeded to cystectomy within 8 weeks after last chemotherapy admini